{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Biological Agent[C307]|Gene Therapy Agent" in comments (approximate match)
Status:
US Approved Rx
(2024)
Source:
NDA217779
(2024)
Source URL:
First approved in 2024
Source:
NDA217779
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
US Approved Rx
(2015)
First approved in 2015
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT01844817: Phase 2 Interventional Completed Pancreatic Cancer
(2013)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT01028495: Phase 2 Interventional Completed Metastatic Pancreatic Cancer
(2009)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT03334617: Phase 2 Interventional Active, not recruiting Non-Small Cell Lung Cancer
(2017)
Source URL:
Class:
NUCLEIC ACID
Status:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT00017407: Phase 3 Interventional Completed Lung Cancer
(2000)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT02658175: Phase 3 Interventional Completed Familial Chylomicronemia Syndrome
(2015)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT00006467: Phase 2 Interventional Completed Pancreatic Cancer
(2001)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Class:
NUCLEIC ACID
